PITTSBURGH, Nov. 5, 2015 /PRNewswire/ -- As part of TissuGlu® Surgical Adhesive's U.S. commercial launch this week, Cohera Medical, Inc. ® is announcing Dr. Joseph Hunstad, board-certified plastic surgeon and co-founder of Hunstad Kortesis Plastic Surgery + MedSpa located in Charlotte, North Carolina, is the first surgeon in his region to perform a commercial procedure using TissuGlu Surgical Adhesive, the only FDA-approved synthetic lysine-based urethane adhesive for internal approximation of tissue in abdominoplasty.
Now commercially available in select cities, TissuGlu Surgical Adhesive is the first FDA-approved synthetic surgical adhesive for internal usage and currently approved for sale in the U.S.
The breakthrough technology is ten times stronger than fibrin-based sealants, TissuGlu Surgical Adhesive is strong, biocompatible and easy to use. Since TissuGlu Surgical Adhesive is a clinically proven alternative to post-operative drains, patients can now undergo an abdominoplasty, also known as tummy tuck, procedure without drains and added scars.
"Patients are less hesitant about an abdominoplasty procedure using TissuGlu. We hear so many patients who worry about recovery time and drain pain. TissuGlu allows patients to get back to normal activities sooner. We are excited to bring this technology to the patient population," said Patrick Daly, President and CEO of Cohera Medical.
Dr. Hunstad extended his industry expertise throughout the development of TissuGlu Surgical Adhesive. "I was proud to participate in the TissuGlu Surgical Adhesive investigational study before it received FDA approval, and now having it as part of my practice, I'm excited to see it create improved outcomes for my patients and those even considering abdominoplasty," said Dr. Hunstad.
"Not having the drains impacted my decision to use TissuGlu. I felt less anxiety about the procedure and recovery time," said Jaycee (patient – two weeks after surgery).
About Cohera Medical
Cohera Medical, Inc. is a rapidly growing medical device company that is actively developing a line of surgical adhesives and sealants. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is indicated for use in the U.S. for the approximation of tissue layers where subcutaneous deadspace exists between the tissue planes in abdominoplasty procedures. Refer to the Directions for Use at http://tissuglu.com/clinicians/dfu/ for complete information on prescribing, usage, contraindications, precautions, warnings, and the risks and benefits of using TissuGlu® Surgical Adhesive. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty, mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. The Company's second product, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval. TissuGlu and Sylys are the first products in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. The other Cohera Medical products are currently indicated for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market.
For more information on TissuGlu Surgical Adhesive, please visit www.TissuGlu.com.
SOURCE Cohera Medical, Inc.